| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662315 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
May, 2029
(5 years from now) | |
| US9408837 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
Feb, 2030
(5 years from now) | |
| US10945960 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(14 years from now) | |
| US10925835 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(14 years from now) | |
| US10350171 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(14 years from now) | |
Consensi is owned by Purple Biotech.
Consensi contains Amlodipine Besylate; Celecoxib.
Consensi has a total of 5 drug patents out of which 0 drug patents have expired.
Consensi was authorised for market use on 31 May, 2018.
Consensi is available in tablet;oral dosage forms.
Consensi can be used as treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate.
The generics of Consensi are possible to be released after 14 June, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 31, 2021 |
Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate
Dosage: TABLET;ORAL
CONSENSI family patents
